Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Design Therapeutics, Inc. (DSGN)

Design Therapeutics Q3 net loss widens to $20.3 million; cash at $208.6 million

Negative Impact 3 of 5 earnings Written later

Design Therapeutics reported third quarter 2026 results on November 4, 2026, with a net loss of $20.3 million, up from $17.0 million a year earlier, as research and development and general and administrative expenses both rose. The company had no revenue in the figures provided, and cash, cash equivalents and investment securities were $208.6 million at September 30, 2026, down from $219.8 million at December 31, 2025, which matters to shareholders because it shows the company funding larger losses from its cash balance.

Key points

  • Q3 2026 net loss was $20.3 million, or $0.32 per share, versus $17.0 million, or $0.30 per share, in Q3 2025.
  • R&D expenses were $16.9 million in Q3 2026 versus $14.6 million a year earlier; G&A expenses were $5.3 million versus $4.7 million.
  • Cash and investment securities were $208.6 million at September 30, 2026, compared with $219.8 million at December 31, 2025.
  • The company expects a registrational plan update for DT-216P2 in Q4 2026 and 12-week RESTORE-FA data in Q1 2027.

The filing

CompanyDesign Therapeutics, Inc. (DSGN)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:08 PM ET
Accession number0001193125-26-447235

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.